Skip to the main content.

Frequently asked questions about KBI Biopharma's

SUREtechnology Platform™

powered by Selexis®, for premium cell line development

Creating Stable, High-Yield, and Clonal Mammalian Cell Lines

Advanced Cell Line Development for New Biologics


The SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the new biologics continuum, spanning discovery to commercialization. 

By combining our proprietary SUREtechnology Platform with our world-class expertise, our cell line development (CLD) services significantly reduce the time, effort, and cost associated with the development of high-performance mammalian cell lines for therapeutic protein production. As a cornerstone of the SUREtechnology Platform, the KBI SURE CHO-M Cell Line is a proprietary, high-performance cell line derived from CHO-K1 cells and used for the production of biotherapeutics. The SURE CHO-M Cell Line was specifically developed to overcome protein expression bottlenecks.

Explore our SUREtechnology platform FAQs, Bispecific Antibody Production FAQs, and more. Learn how we can help you.

Frequently Asked Questions, Answered


SUREtechnology Platform™ tools and technologies FAQs


Experience and Pipeline FAQs


Process and Workflow FAQs


Bispecific Antibody (bsAb) Production FAQs

Ready to Learn More? Get in Touch with our Team.


Contact Us

Never Miss Another Update! 

Subscribe to KBI's Newsletter, The Pulse, to stay up-to-date on all the latest news, articles, and events from KBI Biopharma.